<DOC>
	<DOCNO>NCT02744222</DOCNO>
	<brief_summary>International multi-center double-blind comparative randomize clinical trial evaluate efficacy , safety tolerance BCD-054 ( JSC `` BIOCAD '' , Russia ) 120 mcg 180 mcg intramuscularly , biweekly Avonex® ( Biogen Idec Limited , Great Britain ) 30 mcg , weekly , treatment patient remit multiple sclerosis</brief_summary>
	<brief_title>Comparative Clinical Trial Evaluate Efficacy , Safety Tolerance BCD-054 Avonex® Treatment Patients With Remitting-relapsing Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Written inform consent Diagnosis remit multiple sclerosis accord McDonald criterion ( 2010 ) Minimum 1 relapse last 12 month prior screen Minimum 1 focus brain accumulates gadolinium ( T1weighted image ) 1 new focus ( T2weighted image ) Patient stable neurological state last 30 day prior screen EDSS score 0 4,5 Secondary progressive primary progressive form MS Other disease could influence course disease symptoms assessment Relapse screen 1 study drug injection History use : interferon beta1a , interferon beta 1b , glatiramer acetate last 30 day prior randomization , monoclonal antibody , cytotoxic immunosuppressive drug last 6 month prior randomization , Use corticosteroids intravenously orally last 30 day prior randomization . Intolerance allergy interferon beta excipients BCD054 Avonex® pegylated protein Full list inclusion exclusion criterion find Protocol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>